François Ghiringhelli mainly focuses on Immune system, Cancer research, Immunology, Immunogenic cell death and Cell biology. His Immune system research includes themes of Cancer cell, Chemotherapy, Programmed cell death and Antigen. His research in Cancer research intersects with topics in Cell culture, Cisplatin, CD8 and Cytotoxic T cell, Adoptive cell transfer.
His Immunology study integrates concerns from other disciplines, such as Cancer, Radiation therapy and Myeloid-derived Suppressor Cell. His Immunogenic cell death research is multidisciplinary, incorporating elements of Toll-like receptor and Oxaliplatin. His Cell biology research includes elements of Interleukin 3, Interleukin 21, Cell, Transcription factor and Interleukin 12.
Internal medicine, Oncology, Cancer research, Immune system and Colorectal cancer are his primary areas of study. Internal medicine and Gastroenterology are frequently intertwined in his study. The study incorporates disciplines such as Phases of clinical research, Surgery, FOLFIRINOX and Breast cancer in addition to Oncology.
His Cancer research course of study focuses on Cell and Calreticulin. His Immune system research is multidisciplinary, incorporating elements of Cancer cell, Cancer and Cytotoxic T cell. The various areas that François Ghiringhelli examines in his Cancer cell study include Programmed cell death and Cell biology.
His primary scientific interests are in Internal medicine, Oncology, Cancer research, Colorectal cancer and Immune system. His Internal medicine study which covers Gastroenterology that intersects with Neutropenia. His work in Oncology addresses issues such as Regimen, which are connected to fields such as Docetaxel.
His study in Cancer research is interdisciplinary in nature, drawing from both Immune checkpoint, Cancer, Immunogenic cell death, Immunotherapy and Immunity. His Colorectal cancer research is multidisciplinary, relying on both Aflibercept and MAPK/ERK pathway. His research in Immune system focuses on subjects like Transcription factor, which are connected to Cell biology.
François Ghiringhelli focuses on Internal medicine, Colorectal cancer, Cancer research, Oncology and Immune system. He has included themes like Adjuvant, Clinical endpoint, Chemotherapy and FOXP3 in his Colorectal cancer study. His Cancer research study combines topics in areas such as Cell culture, Psychological repression, Immunogenic cell death, Immunotherapy and Cytotoxic T cell.
He focuses mostly in the field of Immunotherapy, narrowing it down to matters related to Blockade and, in some cases, Antibody and Immunology. In his study, which falls under the umbrella issue of Oncology, Cyclophosphamide, GiST, Metronomic Chemotherapy and Sarcoma is strongly linked to Phases of clinical research. The Immune system study combines topics in areas such as Cancer, Tumor progression and STAT3.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid.
Nature Medicine (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;François Ghiringhelli;François Ghiringhelli;François Ghiringhelli;Gian Maria Fimia.
Nature Medicine (2007)
Immunological aspects of cancer chemotherapy.
Laurence Zitvogel;Laurence Zitvogel;Lionel Apetoh;Lionel Apetoh;François Ghiringhelli;Guido Kroemer;Guido Kroemer.
Nature Reviews Immunology (2008)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong.
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
François Ghiringhelli;Lionel Apetoh;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Laetitia Aymeric;Laetitia Aymeric;Laetitia Aymeric.
Nature Medicine (2009)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
François Ghiringhelli;Cedric Menard;Pierre Emmanuel Puig;Sylvain Ladoire.
Cancer Immunology, Immunotherapy (2007)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death.
Noelia Casares;Marie O. Pequignot;Antoine Tesniere;François Ghiringhelli.
Journal of Experimental Medicine (2005)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
François Ghiringhelli;Nicolas Larmonier;Elise Schmitt;Arnaud Parcellier.
European Journal of Immunology (2004)
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Mickaël Michaud;Mickaël Michaud;Mickaël Michaud;Isabelle Martins;Isabelle Martins;Isabelle Martins;Abdul Qader Sukkurwala;Abdul Qader Sukkurwala;Abdul Qader Sukkurwala;Sandy Adjemian;Sandy Adjemian;Sandy Adjemian.
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide
Sophie Viaud;Sophie Viaud;Fabiana Saccheri;Grégoire Mignot;Takahiro Yamazaki.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: